Clemente Caterina, Elba Silvana, Buongiorno Gianpiero, Guerra Vito, D'Attoma Benedetta, Orlando Antonella, Russo Francesco
Laboratory of Experimental Biochemistry, National Institute for Digestive Sciences, IRCCS S. De Bellis, Castellana Grotte (Ba) Italy.
Liver Int. 2007 Aug;27(6):791-7. doi: 10.1111/j.1478-3231.2007.01485.x.
To evaluate possible modifications in the manganese superoxide dismutase (MnSOD) activity during neoplastic transformation of a cirrhotic liver and to find out whether its assessment may have predictive value to identify cirrhotic patients at a higher risk of hepatocellular carcinoma (HCC).
Seventy-one consecutive subjects with Child-Pugh class A liver cirrhosis were recruited. At the time of enrolment, HCC was diagnosed in 20 cirrhotic patients. The 51 cirrhotic patients without HCC were followed up for the occurrence of tumour by 6-monthly screening for 7 years. During follow-up, 16 patients developed HCC. Seventy healthy subjects formed the control group. MnSOD activity was assayed spectrophotometrically.
Serum MnSOD activity was significantly lower in 70 healthy subjects compared with 51 cirrhotic patients and 20 cirrhotic patients with HCC. Cirrhotic patients who developed HCC during follow-up showed significantly higher values of MnSOD activity than HCC-free patients. The best cut-off of MnSOD activity was 0.40 U/ml. At this cut-off, chi2 analysis revealed that MnSOD activity was significantly different between the HCC-free cirrhotic patients and cirrhotic patients who developed HCC.
The present findings suggest that during neoplastic transformation of cirrhotic liver, an increase in MnSOD activity may occur already during the precancerous phase, making this enzyme a probable malignancy-associated parameter.
评估肝硬化肝脏肿瘤转化过程中锰超氧化物歧化酶(MnSOD)活性可能发生的变化,并探究其评估是否对识别肝细胞癌(HCC)风险较高的肝硬化患者具有预测价值。
招募了71例连续的Child-Pugh A级肝硬化患者。入组时,20例肝硬化患者被诊断为HCC。对51例无HCC的肝硬化患者进行为期7年的每6个月一次的筛查,以追踪肿瘤的发生情况。随访期间,16例患者发生了HCC。70名健康受试者组成对照组。采用分光光度法测定MnSOD活性。
与51例肝硬化患者和20例肝硬化合并HCC患者相比,70名健康受试者的血清MnSOD活性显著降低。随访期间发生HCC的肝硬化患者的MnSOD活性值显著高于无HCC的患者。MnSOD活性的最佳截断值为0.40 U/ml。在此截断值下,卡方分析显示无HCC的肝硬化患者和发生HCC的肝硬化患者之间的MnSOD活性存在显著差异。
目前的研究结果表明,在肝硬化肝脏肿瘤转化过程中,癌前阶段可能就已出现MnSOD活性增加,这使得该酶可能成为与恶性肿瘤相关的参数。